Physician profile
Enrique Criado Pallares
NPI 1053411793
$800,148.88
in general payments reported to CMS, 2019-2025
3 companies · $80K in 2025
The $80K reported for 2025 was more than what 99% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $120K · 2021: $120K · 2022: $120K · 2023: $120K · 2024: $120K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $320K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $320,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $720,000.00 | 2019-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Boston Scientific Corporation | $80,000.00 | 2025 | Enroute Transcarotid Neuroprotection System |
| Abbott Laboratories | $148.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,054,335.64 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Criado Pallares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.